US 12,390,526 B2
Methods for identifying beta-glucan binding to immune cells
William J. Grossman, Third Lake, IL (US); Mary A. Antonysamy, Woodbury, MN (US); Richard M. Walsh, Lino Lakes, MN (US); Mariana I. Nelson, Rosemount, MN (US); Nandita Bose, Plymouth, MN (US); Michael E. Danielson, St. Paul, MN (US); and Kyle S. Michel, Eagan, MN (US)
Assigned to HiberCell, Inc., New York, NY (US)
Filed by HiberCell, Inc., New York, NY (US)
Filed on Dec. 15, 2021, as Appl. No. 17/552,137.
Application 17/552,137 is a division of application No. 14/398,019, granted, now 11,229,701, previously published as PCT/US2013/031606, filed on Mar. 14, 2013.
Claims priority of provisional application 61/640,834, filed on May 1, 2012.
Claims priority of provisional application 61/640,842, filed on May 1, 2012.
Claims priority of provisional application 61/640,397, filed on Apr. 30, 2012.
Prior Publication US 2022/0105181 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 31/716 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/12 (2006.01); C07K 16/14 (2006.01); G01N 33/50 (2006.01); G01N 33/554 (2006.01); G01N 33/569 (2006.01)
CPC A61K 39/39583 (2013.01) [A61K 31/716 (2013.01); A61K 39/39 (2013.01); A61K 39/39558 (2013.01); A61K 39/39575 (2013.01); A61K 45/06 (2013.01); A61K 47/6835 (2017.08); C07K 16/12 (2013.01); C07K 16/14 (2013.01); G01N 33/5047 (2013.01); G01N 33/554 (2013.01); G01N 33/56966 (2013.01); A61K 2039/55583 (2013.01); G01N 2400/24 (2013.01)] 9 Claims
 
1. A method of improving β-glucan immunotherapy for a subject who is a low-binder of β-glucan, the method comprising:
identifying a subject who is a low binder of β-glucan; and
administering to said subject an antibody preparation comprising an anti-β-glucan antibody and a β-glucan immunotherapy, wherein the β-glucan immunotherapy comprises soluble β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose and one or more tumor-related monoclonal antibodies;
wherein a subject is identified as a low-binder of β-glucan if β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose is bound to no more than 10% of the subject's immune cells, or wherein a subject is identified as a low binder of β-glucan if the anti-β-glucan IgG antibody titer of the subject is less than 20,000.